<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940693</url>
  </required_header>
  <id_info>
    <org_study_id>09.008</org_study_id>
    <nct_id>NCT00940693</nct_id>
  </id_info>
  <brief_title>Pilot Study of Duloxetine in Adult Attention Deficit Hyperactivity Disorder(ADHD)</brief_title>
  <official_title>Pilot Study of the Efficacy of Duloxetine in Treating Adults With Attention Deficit Hyperactivity Disorder: a Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether duloxetine is an effective treatment of
      attention deficit disorder in adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of duloxetine on the Conners' Adult attention-Deficit/Hyperactivity Disorder Rating Scale-Observer Report:Screening Version (CAARS-O:SV) in adult ADHD subjects.</measure>
    <time_frame>baseline and week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of duloxetine on the Clinical Global Impression Scale in ADHD adults</measure>
    <time_frame>baseline and week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of duloxetine on the Conners' Adult attention-Deficit/Hyperactivity Disorder Rating Scale-Self Report : Long Version(44) (CAARS-S:L), in adult ADHD subjects.</measure>
    <time_frame>baseline and week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of duloxetine on anxious and depressive symptoms in adult ADHD subjects.</measure>
    <time_frame>baseline and week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of duloxetine on Quality of life in adults with ADHD</measure>
    <time_frame>baseline and week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of duloxetine on executive functions and cognitive performances in adults with ADHD</measure>
    <time_frame>baseline and week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>duloxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duloxetine</intervention_name>
    <description>60 mg capsule once per day for 6 weeks</description>
    <arm_group_label>duloxetine</arm_group_label>
    <other_name>cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one capsule of placebo taken one a day for 6 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of ADHD of at least moderate intensity

          -  Able to give consent

          -  Able to swallow capsules

        Exclusion Criteria:

          -  Allergic or do not tolerate duloxetine

          -  Under psychotherapy for ADHD

          -  Taking a medication that interacts with duloxetine, including all psychotropic
             medication

          -  Treated with medication for ADHD

          -  Unstable medical condition

          -  Severe renal insufficiency

          -  Liver insufficiency

          -  Substance/alcool abuse or dependency in the last 6 months

          -  Pregnancy, nursing or inadequate contraceptive methods

          -  Suicide or homicide risk

          -  Organic brain syndrome

          -  Any diagnosis of lifetime bipolar disorder or psychotic disorder, and any actual
             diagnosis of anxious disorder or major depressive disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Tourjman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Montréal: Hôpital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Tourjman SV, Bilodeau M. Improvement with duloxetine in an adult ADHD patient. J Atten Disord. 2009 Jul;13(1):95-6. doi: 10.1177/1087054708326109. Epub 2009 Apr 9.</citation>
    <PMID>19359667</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2009</study_first_posted>
  <last_update_submitted>December 13, 2010</last_update_submitted>
  <last_update_submitted_qc>December 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Smadar Valérie Tourjman</name_title>
    <organization>Centre Hospitalier Universitaire de Montréal</organization>
  </responsible_party>
  <keyword>Attention Deficit Disorder with Hyperactivity</keyword>
  <keyword>Duloxetine</keyword>
  <keyword>Adult</keyword>
  <keyword>ADDH</keyword>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

